Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • survival outcomes
Proton Pump Inhibitor Use and Survival Outcomes in Newly Diagnosed Glioblastoma: An Evidence-Based Review
Posted inClinical Updates Gastroenterology news Oncology

Proton Pump Inhibitor Use and Survival Outcomes in Newly Diagnosed Glioblastoma: An Evidence-Based Review

Posted by MedXY By MedXY 12/14/2025
Proton pump inhibitor use, particularly potent ALDH1A1-activating PPIs, is associated with worse survival in newly diagnosed glioblastoma, highlighting the need for cautious use and further mechanistic research.
Read More
Evolving Treatment Patterns and Survival Outcomes in Veterans With De Novo Metastatic Hormone-Sensitive Prostate Cancer
Posted innews Oncology Urology

Evolving Treatment Patterns and Survival Outcomes in Veterans With De Novo Metastatic Hormone-Sensitive Prostate Cancer

Posted by MedXY By MedXY 10/30/2025
A retrospective study in US veterans reveals increased use of combination therapies for metastatic hormone-sensitive prostate cancer (mHSPC), showing improved survival over ADT alone. ARPIs and docetaxel demonstrate comparable overall survival, with ARPIs providing longer progression-free survival.
Read More
Impact of Immediate Past Mammography Participation on Outcomes of Screen-Detected Breast Cancer
Posted innews OB/GYN & Women's Health Oncology Radiology Specialties

Impact of Immediate Past Mammography Participation on Outcomes of Screen-Detected Breast Cancer

Posted by MedXY By MedXY 10/04/2025
This cohort study reveals that women with screen-detected breast cancer who missed the immediate prior mammography screening have larger tumors, more advanced disease, and worse breast cancer-specific survival, suggesting delayed detection and poorer prognosis.
Read More
Impact of Treatment Recommendation and Receipt on Survival in Older Women with Early-Stage Cervical Cancer
Posted innews OB/GYN & Women's Health Oncology Specialties

Impact of Treatment Recommendation and Receipt on Survival in Older Women with Early-Stage Cervical Cancer

Posted by MedXY By MedXY 09/24/2025
This study reveals that among women aged 65 and older with early-stage cervical cancer, those who receive recommended treatment—surgery and/or radiotherapy—exhibit significantly higher survival rates, emphasizing the need to overcome treatment barriers in this population.
Read More
Unraveling the Prognostic Impact of Co-Occurring High-Risk Cytogenetic Abnormalities in Multiple Myeloma
Posted inClinical Updates Hematology-Oncology Specialties

Unraveling the Prognostic Impact of Co-Occurring High-Risk Cytogenetic Abnormalities in Multiple Myeloma

Posted by MedXY By MedXY 09/09/2025
A meta-analysis of 24 trials involving 13,926 patients establishes that concurrent high-risk cytogenetic abnormalities markedly worsen progression-free and overall survival in both newly diagnosed and relapsed multiple myeloma, underscoring the need for targeted therapeutic strategies.
Read More
Local Recurrence and Survival Outcomes in Non-Lentigo Maligna and Non-Acral Lentiginous Melanoma In Situ: Evidence from a 30-Year Cohort Study
Posted innews Oncology Specialties

Local Recurrence and Survival Outcomes in Non-Lentigo Maligna and Non-Acral Lentiginous Melanoma In Situ: Evidence from a 30-Year Cohort Study

Posted by MedXY By MedXY 09/03/2025
This retrospective cohort study evaluates local recurrence and survival in non-LM/non-ALM melanoma in situ, revealing minimal recurrence rates when diagnostic excisional biopsies have clear margins, questioning the necessity of routine wide excisions.
Read More
Age-Dependent Survival Outcomes in Early-Stage Endometrial Cancer: Fertility-Preserving Hormonal Therapy Versus Hysterectomy
Posted innews OB/GYN & Women's Health Oncology Specialties

Age-Dependent Survival Outcomes in Early-Stage Endometrial Cancer: Fertility-Preserving Hormonal Therapy Versus Hysterectomy

Posted by MedXY By MedXY 08/31/2025
Fertility-preserving hormonal therapy for early-stage endometrial cancer shows comparable 5-year survival to hysterectomy in women under 40, but a significantly higher mortality risk in those aged 40-49 years, highlighting age as a critical factor in treatment decisions.
Read More
Adjuvant Chemoradiotherapy in Oral Cavity SCC: Distinguishing Benefits Between Minor and Major Extranodal Extension
Posted inOncology Radiology Specialties

Adjuvant Chemoradiotherapy in Oral Cavity SCC: Distinguishing Benefits Between Minor and Major Extranodal Extension

Posted by MedXY By MedXY 08/23/2025
This multicenter study clarifies that adjuvant chemotherapy improves survival outcomes in oral cavity squamous cell carcinoma with major extranodal extension but offers no clear benefit in cases with minor extranodal extension.
Read More
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer: Impact on Survival Outcomes
Posted inFamily Medicine & Nutrition news Oncology Specialties

Structured Exercise after Adjuvant Chemotherapy for Colon Cancer: Impact on Survival Outcomes

Posted by MedXY By MedXY 08/19/2025
A 3-year structured exercise program post-adjuvant chemotherapy significantly improves disease-free and overall survival in colon cancer patients, based on the CHALLENGE phase 3 RCT involving 889 patients.
Read More
  • Bone Metabolism Biomarkers: A New Frontier in Predicting Cardiovascular Risk for Diabetes and Renal Disease
  • Stockholm3 Versus PSA in Prostate Cancer Screening: A Synthesis of 9-year Outcomes, Repeat Screening, and Multiethnic Validation
  • Overcoming Resistance in ALK-Positive NSCLC: The Emergence of APG-2449 as a Novel FAK and Third-Generation TKI
  • Systemic Atezolizumab and Intravesical BCG in High-Risk NMIBC: Lessons from the ALBAN (GETUG-AFU 37) Phase III Trial
  • Datopotamab Deruxtecan Redefines Progression-Free Survival in HR+/HER2- Breast Cancer Despite Neutral Overall Survival Results
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology exercise health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Pediatrics Physical Activity Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial SGLT2 inhibitors stroke targeted therapy type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in